Second-Line Therapies in Metastatic Urothelial Carcinoma

Narayanan Sujata; Harshman Lauren C.; Srinivas Sandy

首页> 外文期刊>Hematology/Oncology Clinics of North America >Second-Line Therapies in Metastatic Urothelial Carcinoma

【24h】

Second-Line Therapies in Metastatic Urothelial Carcinoma

机译：转移性尿路上皮癌的二线治疗

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

Patients with relapsed or refractory urothelial carcinoma (UC) face a poor prognosis and a dearth of available treatment options that improve their survival. End-organ function and performance status play a vital role in the choice of second-line therapies. Evidence supporting the use of cytotoxic chemotherapy, as single agents or in combination, arises from small phase 2 studies with modest responses. With the evolution of genomic testing in UC, several pathways amenable to available targeted therapies have emerged. Encouraging patient participation in clinical trials is critical to improve patient outcomes and to advance the current modest treatment armamentarium.

机译：患有复发性或难治性尿路上皮癌（UC）的患者预后较差，缺少可提高其生存率的可用治疗选择。最终器官的功能和表现状态在选择二线治疗中起着至关重要的作用。小规模的2期研究，反应中等，支持单用或联合使用细胞毒性化学疗法的证据。随着UC中基因组测试的发展，出现了几种适用于可用靶向疗法的途径。鼓励患者参与临床试验对于改善患者预后并推进目前适度的治疗装备至关重要。

著录项

来源
《Hematology/Oncology Clinics of North America》 |2015年第2期|共19页
作者
Narayanan Sujata; Harshman Lauren C.; Srinivas Sandy;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类肿瘤学;
关键词
Refractory; Therapies in urothelial cancer; Chemotherapy; Targeted; Immunotherapy;

机译：难治性;尿路上皮癌的治疗;化学疗法;靶向疗法;免疫疗法;

相似文献

外文文献
中文文献
专利

1. Re: Second-Line Chemotherapy in Older Patients with Metastatic Urothelial Carcinoma: Pooled Analysis of 10 Second-Line Studies Editorial Comment [J] . Griebling Tomas L. The Journal of Urology . 2018,第3期

机译：Re：老年转移性尿路上皮癌患者的二线化疗：10次初级研究汇总分析编辑评论
2. Second-line therapy for metastatic urothelial carcinoma: Defining the best treatment option among immunotherapy, chemotherapy, and antiangiogenic targeted therapies. A systematic review and meta-analysis [J] . Ciccarese Chiara, Iacovelli Roberto, Bria Emilio, Seminars in Oncology . 2019,第1期

机译：二线治疗转移性尿路上皮癌：在免疫疗法，化疗和抗血管生成靶向治疗中定义最佳治疗选择。系统审查和荟萃分析
3. Clinical significance of a second-line chemotherapy regimen with paclitaxel, ifosfamide and nedaplatin for metastatic urothelial carcinoma after failure of cisplatin-based chemotherapy [J] . Kobayashi Keita, Matsuyama Hideyasu, Shimizu Kosuke, Japanese journal of clinical oncology. . 2016,第8期

机译：紫杉醇，异环磷酰胺和奈达铂二线化疗方案对以顺铂为基础的化疗失败后转移性尿路上皮癌的临床意义
4. Weekly Paclitaxel Therapy as the Second-line Chemotherapy to TS-1 for Advanced/Metastatic Gastric Cancer [C] . M. Fujishima, H. Imamura, H. Furukawa, International Gastric Cancer Congress . 2005

机译：每周紫杉醇治疗作为先进/转移性胃癌的二线化学疗法至TS-1
5. Beyond body mass index: The impact of sarcopenia and adiposity on clinical and oncologic outcomes following radical cystectomy for urothelial carcinoma [D] . Psutka, Sarah P. 2015

机译：超越体重指数：SARCOPENIA和肥胖对尿路膀胱切除术后的临床和肿瘤结果的影响
6. Avelumab as second-line therapy for metastatic platinum-treated urothelial carcinoma in the phase Ib JAVELIN Solid Tumor study: 2-year updated efficacy and safety analysis [O] . Andrea B Apolo, John A Ellerton, Jeffrey R Infante, 2020

机译：Avelumab作为转移性铂治疗的尿路上皮癌中的二线治疗IB标枪固体瘤研究：2年更新的疗效和安全分析
7. Avelumab as second-line therapy for metastatic, platinum-treated urothelial carcinoma in the phase Ib JAVELIN Solid Tumor study: 2-year updated efficacy and safety analysis [O] . Andrea B Apolo, John A Ellerton, Jeffrey R Infante, 2020

机译：Avelumab作为转移性，铂治疗的尿路上皮癌中的二线治疗IB标枪固体瘤研究：2年更新的疗效和安全分析

Second-Line Therapies in Metastatic Urothelial Carcinoma

摘要

著录项

相似文献

相关主题

期刊订阅